Contact Us

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Hemorrhagic shock is a rare condition which occurs in many gynecological or obstetrical situations. In this condition, reduction in blood volume leads to sympathetic compensation by tachycardia, peripheral vasoconstriction, and increased myocardial contractility. This can increase the myocardial oxygen demand. As per the World Health Organization (WHO), trauma remains one of the leading causes of death globally with half of the cases attributed to hemorrhages.

According to the National Trauma Institute (NTI), trauma is the third leading cause of mortality across the globe in the age group ranging from 1 to 44 years. Major hemorrhage is responsible for 30-40% mortality among trauma patients. Moreover, in patients with traumatic injuries to the central nervous system, hemorrhagic shock is the second leading cause of morbidity and mortality despite the fact that it could be reversible and preventable.

The growing burden of chronic diseases and the increase in consumption of anti-hypertensive drugs is expected to drive the growth of the global hemorrhagic shock treatment market during the forecast period. For instance, according to the World Health Organization (WHO), the rate of chronic disease burden is estimated to increase from 47% in 2001 to 57% by 2020.

Hemorrhagic Shock Treatment Market - Impact of Coronavirus (Covid-19) Pandemic

The ongoing COVID-19 pandemic is posing major challenges in the management of important medical emergencies such as hemorrhage and other chronic conditions. Hemorrhagic shock is an important health emergency with significant morbidity and mortality and needs timely treatment. However, higher COVID-19 cases, lack of facilities, and infrastructure is posing challenge for the healthcare system to treat patients with other morbidities.

The all-inclusive version of the report will include the impact of COVID-19 and the probable changes in the future outlook of the industry, by taking into account the technological, social, political, and economical parameters.

The global hemorrhagic shock treatment market is estimated to be valued at US$ 175.4 million in 2020 and is expected witness a CAGR of 4.0% during the forecast period (2020-2027).

Figure 1: Global Hemorrhagic Shock Treatment Market Share (%) Analysis, By Distribution Channel, 2020.

Hemorrhagic Shock Treatment  | Coherent Market Insights

An increase in the number of clinical trials and collaborative agreements for hemorrhagic shock treatment are expected to propel the growth of the global hemorrhagic shock treatment market.

Key players in the market are involved in research & d evelopment of therapies and drugs for the treatment of hemorrhagic shock. Strategic collaborations, licensing agreements, and drug approvals are expected to drive growth of the global hemorrhagic shock treatment market during the forecast period.

In February 2015, Leading BioSciences received FDA IND clearance for phase II clinical trial using LB1148 (tranexamic acid) for the treatment of hemorrhagic shock. According to the company, the U.S. Food and Drug Administration (FDA) approval for conducting a well-designed phase II safety and efficacy trial for LB-1148 is a crucial step in advancing the company’s development plan.

In January 2017, NuvOxPharma LLC and Jiangsu Nhwa Pharmaceutical Co., Ltd. entered a licensing agreement for the development and sales of NVX-408 in China for treatment of perioperative blood loss and hemorrhagic shock. NVX-408 is injected intravenously and is an oxygen therapeutic that flows through the lungs and collects oxygen, then flowing through the blood passing hypoxic tissue and releases oxygen. According to pre-clinical studies, NVX-408 can improve survival rate during severe blood loss.

Global Hemorrhagic Shock Treatment Market - Restraints

The dearth of healthcare services and costs associated with the treatment of hemorrhagic shock are major factors restraining the growth of the market across the globe. Moreover, the lack of advanced healthcare facilities in low- and mid-income countries in Africa is expected to hamper the overall market growth.

request-sample

Hemorrhagic Shock Treatment Market Report Coverage

Report Coverage Details
Base Year: 2019 Market Size in 2019: US$ 175.4 Mn
Historical Data for: 2016 to 2019 Forecast Period: 2020 to 2027
Forecast Period 2020 to 2027 CAGR: 4.0% 2027 Value Projection: US$ 230.9 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Drug: NVX-408, YW-356, LB-1148, Neutrolide, Others.
  • By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Channels.
Companies covered:

Biomedica Management Corporation, NuvOxPharma LLC, Leading BioSciences, Inc., F. Hoffmann-La Roche Ltd, Bristol-Myers Squibb Company, Boehringer Ingelheim International GmbH, Johnson & Johnson Services Inc, AstraZeneca, Daiichi Sankyo Company, Limited, Teva Pharmaceutical Industries Ltd, Novartis AG, ZydusCadila, and Amneal Pharmaceuticals LLC.

Growth Drivers:
  • The growing burden of chronic diseases
  • Changes in lifestyle and rising consumption of anti-hypertensive drugs
Restraints & Challenges:
  • High costs associated with the hemorrhagic shock treatment
  • Stringent regulatory for using hemorrhagic shock drug

Global Hemorrhagic Shock Treatment Market – Regional Analysis

The market North America accounted for the largest share in the hemorrhagic shock treatment in 2019 due to the growing demand for disease-specific treatment, the increasing focus on research & development, and approvals for the treatment of hemorrhagic shock. For instance, in February 2017, the U.S. Army Institute of Surgical Research (USAISR) received FDA clearance for its hemorrhagic shock device. The researchers of USAISR collaborated with engineers and scientists at the University of Colorado and Flashback Technologies Inc. to develop an algorithm to detect when a patient is going into hemorrhagic shock. The tiny device is the first medical monitoring technology capable of early detection of impending circulatory shock in trauma patients.

In October 2019, scientists at the Feinstein Institutes for Medical Research completed a study that involves bio-electronic medicine strategies for hemorrhagic shock (HS) treatment. The positive findings of this study have been published in the Springer Nature journal.

Figure 2: Global Hemorrhagic Shock Treatment Market Value (US$ Mn) & Y-o-Y Growth (%), 2017-2027

Hemorrhagic Shock Treatment  | Coherent Market Insights

Global Hemorrhagic Shock Treatment Market - Competitive Landscape

Key players operating in the global hemorrhagic shock treatment market are Biomedica Management Corporation, NuvOxPharma LLC, Leading BioSciences, Inc., F. Hoffmann-La Roche Ltd, Bristol-Myers Squibb Company, Boehringer Ingelheim International GmbH,Johnson & Johnson Services Inc, AstraZeneca, Daiichi Sankyo Company, Limited, Teva Pharmaceutical Industries Ltd, Novartis AG, ZydusCadila, and Amneal Pharmaceuticals LLC.

Hemorrhagic shock is a condition that results in reduced tissue perfusion and inadequate delivery of oxygen and nutrients to cells. A traumatic injury may lead to hemorrhagic shock if bleeding is not stopped immediately. The primary treatment for hemorrhagic shock is to immediately control the source of bleeding and to replace the fluid. In CHS (Controlled Hemorrhagic Shock), the fluid replacement is to normalise hemodynamic parameters where the source of bleeding has been stopped.

Global Hemorrhagic Shock Treatment Market Dynamics

Factors such as the increasing consumption of anti-hypertensive drugs and burden of chronic diseases across the globe are expected to propel the market growth. For instance, according to statistics provided by the World Health Organization, the chronic disease burden was 47% in 2001 and is predicted to increase to 57% by 2020.

Moreover, a rise in the number of ischemic strokes, coupled with the increasing consumption of tobacco is also expected to drive the market growth. According to the World Stroke Organization (WSO), there were over 9.5 million novel cases of ischemic stroke in 2016, of which 52% were men.

Key features of the study:

  • This report provides in-depth analysis of the global hemorrhagic shock treatment market, market size (US$ Mn), and compound annual growth rate (CAGR (%)) for the forecast period (2020-2027), considering 2019 as the base year
  • It elucidates potential revenue opportunity across different segments and explains the attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, product launches or approvals, market trends, regional outlook, and competitive strategies adopted by leading players
  • It profiles key players in the global hemorrhagic shock treatment market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, key developments, and strategies
  • Key players covered as a part of this study are F. Hoffmann-La Roche Ltd, Biomedica Management Corporation, Leading BioSciences, Inc., NuvOx Pharma LLC, Bristol-Myers Squibb Company, Johnson & Johnson Services Inc, Boehringer Ingelheim International GmbH, AstraZeneca, Teva Pharmaceutical Industries Ltd, Daiichi Sankyo Company, Limited, Novartis AG, Amneal Pharmaceuticals LLC, and Zydus Cadila.
  • Insights from this report would allow marketers and management authorities of companies to make informed decisions with respect to future product launches, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
  • The global hemorrhagic shock treatment market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers in the global hemorrhagic shock treatment market, research and consulting firms, new entrants, and financial analysts.

Detailed Segmentation:

  • Global Hemorrhagic Shock Treatment Market, By Drug:
    • NVX-408
    • YW-356
    • LB-1148
    • Neutrolide
    • Others
  • Global Hemorrhagic Shock Treatment Market, By Distribution Channel:
    • Retail Pharmacy
    • Hospital Pharmacy
    • Online Channels
  • Global Hemorrhagic Shock Treatment Market, By Region:
    • North America
      • By Country:
        • U.S.
        • Canada
      • By Drug:
        • NVX-408
        • YW-356
        • LB-1148
        • Neutrolide
        • Others
      • By Distribution Channel:
        • Retail Pharmacy
        • Hospital Pharmacy
        • Online Channels
    • Europe
      • By Country:
        • U.K.
        • Germany
        • Italy
        • Spain
        • France
        • Russia
        • Rest of Europe
      • By Drug:
        • NVX-408
        • YW-356
        • LB-1148
        • Neutrolide
        • Others
      • By Distribution Channel:
        • Retail Pharmacy
        • Hospital Pharmacy
        • Online Channels
    • Asia Pacific
      • By Country:
        • Australia
        • India
        • China
        • Japan
        • ASEAN
        • South Korea
        • Rest of Asia Pacific
      • By Drug:
        • NVX-408
        • YW-356
        • LB-1148
        • Neutrolide
        • Others
      • By Distribution Channel:
        • Retail Pharmacy
        • Hospital Pharmacy
        • Online Channels
    • Latin America
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
      • By Drug:
        • NVX-408
        • YW-356
        • LB-1148
        • Neutrolide
        • Others
      • By Distribution Channel:
        • Retail Pharmacy
        • Hospital Pharmacy
        • Online Channels
    • Middle East
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
      • By Drug:
        • NVX-408
        • YW-356
        • LB-1148
        • Neutrolide
        • Others
      • By Distribution Channel:
        • Retail Pharmacy
        • Hospital Pharmacy
        • Online Channels
    • Africa
      • By Country/Region:
        • South Africa
        • Central Africa
        • North Africa
      • By Drug:
        • NVX-408
        • YW-356
        • LB-1148
        • Neutrolide
        • Others
      • By Distribution Channel:
        • Retail Pharmacy
        • Hospital Pharmacy
        • Online Channels
  • Company Profiles
    • F. Hoffmann-La Roche Ltd
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies
    • Biomedica Management Corporation
    • Leading BioSciences, Inc.
    • NuvOx Pharma LLC
    • Bristol-Myers Squibb Company
    • Johnson & Johnson Services Inc.
    • Boehringer Ingelheim International GmbH
    • AstraZeneca
    • Teva Pharmaceutical Industries Ltd.
    • Daiichi Sankyo Company, Limited
    • Novartis AG
    • Amneal Pharmaceuticals LLC
    • Zydus Cadila

 “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Overview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Drug
      • Market Snippet, By Distribution Channel
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Technological Advancements in Hemorrhagic Shock Treatment
    • Key Developments
    • Acquisition, Collaborations & Partnerships
    • Epidemiology
    • Pipeline Analysis
    • PEST Analysis
  4. Global Hemorrhagic Shock Treatment Market, Impact of Coronavirus (COVID-19) Pandemic
    • Pre-COVID situation
    • Post-COVID demand
    • Need for Hemorrhagic Shock Treatment
    • Recommendations and guidelines by regulatory bodies
  5. Global Hemorrhagic Shock Treatment Market, By Drug, 2016 – 2027, (US$ Million)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • NVX-408
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • YW-356
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • LB-1148
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Neutrolide
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
  6. Global Hemorrhagic Shock Treatment Market, By Distribution Channel, 2016 – 2027, (US$ Million)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Hospital Pharmacy
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Retail Pharmacy
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Online Channels
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
  7. Global Hemorrhagic Shock Treatment Market, By Region, 2016 – 2027, (US$ Million)
    • Introduction
      • Market Share Analysis, By Region, 2020 and 2027(%)
      • Y-o-Y Growth Analysis, By Region, 2017 –2027
      • Regional Trends
    • North America
      • Market Size and Forecast, By Drug, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
        • U.S.
        • Canada
    • Europe
      • Market Size and Forecast, By Drug, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Drug, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
        • China
        • Japan
        • India
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • Market Size and Forecast, By Drug, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Africa
      • Market Size and Forecast, By Drug, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country/Region, 2016 – 2027, (US$ Million)
        • North Africa
        • Central Africa
        • South Africa
    • Middle East
      • Market Size and Forecast, By Drug, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
        • GCC
        • Israel
        • Rest of Middle East
  8. Competitive Landscape
    • Company Profiles
      • Biomedica Management Corporation
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • NuvOxPharma LLC
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Leading BioSciences, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • F. Hoffmann-La Roche Ltd.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Bristol-Myers Squibb Company
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Boehringer Ingelheim International GmbH
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Johnson & Johnson Services Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • AstraZeneca
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Daiichi Sankyo Company, Limited
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Teva Pharmaceutical Industries Ltd.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Novartis AG
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • ZydusCadila
        •  Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Amneal Pharmaceuticals LLC
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
  9. Section
    • References
    • Research Methodology
    • About Us and Sales Contact

*Browse 24 market data tables and 30 figures on "Global Hemorrhagic Shock Treatment Market” - Forecast to 2027”

Frequently Asked Questions

The global hemorrhagic shock treatment market is expected to witness a CAGR of 4.01% during the forecast period (2020-2027).
The global hemorrhagic shock treatment market is estimated to be valued at US$ 175.4 million in 2020.
The prominent players in the global hemorrhagic shock treatment market are Biomedica Management Corporation, NuvOxPharma LLC, Leading BioSciences, Inc., F. Hoffmann-La Roche Ltd, Bristol-Myers Squibb Company, Boehringer Ingelheim International GmbH, Johnson & Johnson Services Inc, AstraZeneca, Daiichi Sankyo Company, Limited, Teva Pharmaceutical Industries Ltd, Novartis AG, ZydusCadila, and Amneal Pharmaceuticals LLC.
The global hemorrhagic shock treatment market is expected to be valued at US$ 230.9 million in 2027.
The major region in the global hemorrhagic shock treatment market is North America.
Rising consumption of anti-hypertensive drugs, lifestyle changes, and the growing burden of chronic diseases.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner